ECOG-ACRIN Cancer Research Group

02/27/2026

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: https://bit.ly/mm1oa-ea02-study

02/27/2026

Clinical trial EAF223/GABLE, led by Dr. Daniel Barboriak of Duke Radiology, aims to help newly diagnosed patients with by testing a new treatment approach. Learn more: https://bit.ly/gable-trial

02/27/2026

: ICYMI, new data from PrECOG Cancer Research Group PrE0405, presented at , showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell . More: https://bit.ly/4aReE69

BackgroundMantle cell lymphoma (MCL) is an incurable form of aggressive non-Hodgkin lymphoma. Treatment choice at diagnosis is based on tolerability o…

02/26/2026

Debate continues: should move earlier in undifferentiated pleomorphic ( ) care? Insights from Dr. Seth Pollack and the ECOG-ACRIN EA7222 trial shed light on evolving treatment paradigms. Watch the video:

Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.

02/26/2026

In clinical trial EA2222/PUMP, investigators are testing pump chemotherapy in addition to standard-of-care (SOC) chemotherapy versus SOC chemotherapy alone for patients with unresectable colorectal cancer liver metastases. For more: https://bit.ly/ea2222-pump

02/26/2026

Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: https://bit.ly/ea8231-study

02/26/2026

Help potentially improve the future of head and neck cancer treatment. Take part in clinical study EA3191 for patients with squamous cell carcinoma of the head and neck (HNSCC) that has come back. Learn more: https://bit.ly/ea3191-study

02/25/2026

Dr. Seth Pollack of Lurie Cancer Center is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated sarcomas. More here: https://bit.ly/EA7222

02/25/2026

In the Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with . Learn more: http://bit.ly/ComboMATCH

02/24/2026

In The Washington Post, Dr. Leana Wen argues for more personalized screening—moving beyond 1-size-fits-all mammograms. That’s exactly what our trial is evaluating: how 3D tomo compares to standard mammography & who benefits most. More: https://bit.ly/4rYQHRf

02/24/2026

Patients with aggressive B-cell lymphoma that has recurred or is resistant to treatment may be eligible to participate in clinical trial EA4231. Learn more here: https://bit.ly/EA4231

02/24/2026

Clinical trial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial